VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Adult men who have sex with men, and transgender  │ Adult men who have sex with men, and transgender  │     100 │
│ women                                             │ women                                             │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Unaware of HIV status at enrollment in follow-up  │ Unaware of HIV status at enrollment in follow-up  │     100 │
│ cohort                                            │ cohort                                            │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ High risk for HIV infection                       │ High risk for HIV infection                       │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Willing to test for HIV                           │ Willing to test for HIV                           │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ No prior ART, including prior administration of   │ No prior ART, including prior administration of   │     100 │
│ pre- and post-exposure prophylaxis in the last 30 │ pre- and post-exposure prophylaxis in the last 30 │         │
│ days                                              │ days                                              │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Willing to provide informed consent               │ Willing to provide informed consent               │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Prior receipt of investigational anti-HIV vaccine │ Prior receipt of investigational anti-HIV vaccine │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Known allergy/sensitivity or any hypersensitivity │ Known allergy/sensitivity or any hypersensitivity │     100 │
│ to components of study drugs (ART) or their       │ to components of study drugs (ART) or their       │         │
│ formulations                                      │ formulations                                      │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Active drug or alcohol use or dependence that     │ Active drug or alcohol use or dependence that     │     100 │
│ would interfere with adherence to study           │ would interfere with adherence to study           │         │
│ requirements                                      │ requirements                                      │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Serious medical or psychiatric illness that would │ Serious medical or psychiatric illness that would │     100 │
│ interfere with the ability to adhere to study     │ interfere with the ability to adhere to study     │         │
│ requirements                                      │ requirements                                      │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Chronic or acute hepatitis B infection            │ Chronic or acute hepatitis B infection            │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Use of female hormonal products based on estrogen │ Use of female hormonal products based on estrogen │     100 │
│ or derivatives                                    │ or derivatives                                    │         │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must be MALE                                      │ Willing to test for HIV                            │      23 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systemic chemotherapeutic agents                  │ Use of female hormonal products based on estrogen  │      38 │
│                                                   │ or derivatives                                     │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                 │ Adult men who have sex with men, and transgender   │      39 │
│                                                   │ women                                              │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ongoing therapy with any of the following         │ Adult men who have sex with men, and transgender   │      40 │
│                                                   │ women                                              │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Immunomodulatory treatments including             │ Adult men who have sex with men, and transgender   │      40 │
│ Interleukin-2                                     │ women                                              │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systemic corticosteroids. Short course less than  │ Serious medical or psychiatric illness that would  │      44 │
│ or equal to 21 days of corticosteroids is allowed │ interfere with the ability to adhere to study      │         │
│                                                   │ requirements                                       │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Nephrotoxic systemic agents, including            │ Ongoing therapy with any of the following:         │      48 │
│ aminoglycosides, amphotericin B, cidofovir,       │ Systemic corticosteroids. Short course less than   │         │
│ cisplatin, foscarnet, pentamidine                 │ or equal to 21 days of corticosteroids is allowed; │         │
│                                                   │ Systemic chemotherapeutic agents; Nephrotoxic      │         │
│                                                   │ systemic agents, including aminoglycosides,        │         │
│                                                   │ amphotericin B, cidofovir, cisplatin, foscarnet,   │         │
│                                                   │ pentamidine; Immunomodulatory treatments including │         │
│                                                   │ Interleukin-2; Investigational agents              │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Investigational agents                            │ Prior receipt of investigational anti-HIV vaccine  │      51 │
╘═══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                           │ CHIA Criteria                                      │   Score │
╞═════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Nephrotoxic systemic agents, including      │ Ongoing therapy with any of the following:         │      48 │
│ aminoglycosides, amphotericin B, cidofovir, │ Systemic corticosteroids. Short course less than   │         │
│ cisplatin, foscarnet, pentamidine           │ or equal to 21 days of corticosteroids is allowed; │         │
│                                             │ Systemic chemotherapeutic agents; Nephrotoxic      │         │
│                                             │ systemic agents, including aminoglycosides,        │         │
│                                             │ amphotericin B, cidofovir, cisplatin, foscarnet,   │         │
│                                             │ pentamidine; Immunomodulatory treatments including │         │
│                                             │ Interleukin-2; Investigational agents              │         │
╘═════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 74.80952380952381
OverAll Ratio: 86.4047619047619
